Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | HLCS | P50747 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581602 | 0.98 | ALDH1A1 (0.39) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL2579275 | 0.98 | ALDH1A1 (0.39) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL2108191 | 0.84 | — | — | |
| SCHEMBL2326236 | 0.81 | ALDH1A1 (0.46) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL8532189 | 0.81 | ALDH1A1 (0.46) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL2204763 | 0.81 | ALDH1A1 (0.46) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL11388793 | 0.81 | ALDH1A1 (0.46) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL2734736 | 0.81 | ALDH1A1 (0.46) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL8537115 | 0.81 | ALDH1A1 (0.46) | ALDH1A1S1PR3HLCSEPHX1 | |
| SCHEMBL3696117 | 0.81 | NOS3 (0.35) | ALDH1A1S1PR3HLCSEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1053665-C | 2,4-diaryl-1,3-dithiolanes, 2,4-diaryl-1,3-dioxolanes, 2,4-diaryl-1, 3-oxathiolanes, and 2,5-diaryl-1, 3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or.......... | INNOVATIVE TECH CENTER (US) | 2000-06-21 | — | — | CN | disclosed |